Pheochromocytoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
(Blanked the page) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Pheochromocytoma}} | |||
{{CMG}} | |||
==Overview== | |||
==Medical Therapy== | |||
Any surgical option requires prior treatment with both the non-specific alpha adrenoceptor blocker [[Phenoxybenzamine]] to counteract hypertension and the beta-1 adrenoceptor antagonist [[Atenolol]] to reduce cardiac output. Given before surgery, these can also block the effect of a sudden release of adrenaline during tumour removal, which would otherwise endanger the anaethetised patient. | |||
==References== | |||
{{reflist|2}} | |||
{{WH}} | |||
{{WS}} | |||
[[Category:Endocrinology]] | |||
[[Category:Oncology]] | |||
Revision as of 16:21, 11 September 2012
|
Pheochromocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pheochromocytoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Pheochromocytoma medical therapy |
|
Risk calculators and risk factors for Pheochromocytoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
Any surgical option requires prior treatment with both the non-specific alpha adrenoceptor blocker Phenoxybenzamine to counteract hypertension and the beta-1 adrenoceptor antagonist Atenolol to reduce cardiac output. Given before surgery, these can also block the effect of a sudden release of adrenaline during tumour removal, which would otherwise endanger the anaethetised patient.